论文部分内容阅读
目的研究hMLH1、hMSH2在原发性肝癌组织中的表达及与临床病理特征的关系。方法应用SABC免疫组化法,检测hMLH1、hMSH2在37例原发性肝癌组织中的表达。结果hMLH1、hMSH2在癌组织中的阳性率及其评分分别为48.7%(1.65±1.70)分、59.5%(2.30±1.96)分,明显低于癌旁组织83.8%(3.30±1.37)分、86.5%(4.30±2.01)分及正常肝组织88.2%(3.88±1.98)分、82.3%(4.29±1.83)分(P<0.01);hMLH1、hMSH2的表达与原发性肝癌组织分化程度有关,hMLH1的表达与AFP是否阳性有关,二者与其它临床病理特征无关。结论hMLH1、hMSH2在原发性肝癌组织发生发展中起重要抑制作用。hMLH1、hMSH2可作为预测原发性肝癌组织预后的重要指标-。
Objective To study the expression of hMLH1 and hMSH2 in primary hepatocellular carcinoma and its relationship with clinicopathological features. Methods SABC immunohistochemical method was used to detect the expression of hMLH1 and hMSH2 in 37 primary hepatocellular carcinoma tissues. Results The positive rates of hMLH1 and hMSH2 in cancer tissues were 48.7% (1.65 ± 1.70) and 59.5% (2.30 ± 1.96), respectively, which were significantly lower than that in paracancer tissues 83.8% (3.30 ± 1.37) and 86.5 (4.30 ± 2.01) and normal liver tissue (88.2%, 3.88 ± 1.98) and 82.3% (4.29 ± 1.83), respectively (P <0.01). The expression of hMLH1 and hMSH2 was related to the degree of differentiation of primary liver cancer. The expression of hMLH1 The expression of AFP is positive, both have nothing to do with other clinicopathological features. Conclusion hMLH1 and hMSH2 play important roles in the development of primary hepatocellular carcinoma. hMLH1, hMSH2 can be used as an important index to predict the prognosis of primary liver cancer.